Market Closed -
Other stock markets
|
After market 17:49:31 | |||
27.46 EUR | +2.83% | 27.34 | -0.44% |
09-16 | Bayer: results for prostate cancer treatment | CF |
09-16 | BAYER AG : JP Morgan reiterates its Neutral rating | ZD |
P/E ratio | Price to Book | PEG | EV / Sales | EV / EBITDA | EV / EBIT | Yield (Y) | Capi. ($) | ||
---|---|---|---|---|---|---|---|---|---|
11.26x | 0.7583 | -0.06x | 1.28x | 5.76x | 9.11x | +0.41% | 29.19B | ||
59.55x | 41.03 | 0.36x | 18.44x | 44.85x | 48.62x | +0.56% | 832B | ||
40.6x | 28.45 | 1.85x | 14.14x | 28.79x | 31.95x | +1.24% | 609B | ||
21.38x | 5.690 | -0.5x | 4.62x | 13.07x | 14.83x | +2.80% | 402B | ||
38.09x | 41.37 | 0.43x | 7.21x | 15.57x | 16.16x | +3.18% | 346B | ||
15.73x | 6.092 | 0x | 4.99x | 11.44x | 12.95x | +2.61% | 299B | ||
15.84x | 5.786 | 0.96x | 3.75x | 9.69x | 10.89x | +3.73% | 251B | ||
28.42x | 5.846 | 0.61x | 5.11x | 15.29x | 15.75x | +1.95% | 246B | ||
21.61x | 5.283 | -0.88x | 4.98x | 12.6x | 13.28x | +3.25% | 236B | ||
51.65x | 35.90 | -1.08x | 6.94x | 12.15x | 15.5x | +2.74% | 180B | ||
22.08x | 1.944 | 0.08x | 3.76x | 10.28x | 12.34x | +5.54% | 170B | ||
19.44x | 1.697 | 0.83x | 2.9x | 10.03x | 11.14x | +3.75% | 144B | ||
308.92x | 5.259 | -3.29x | 4.36x | 11.97x | 16.28x | +3.70% | 104B | ||
-25.34x | 5.389 | 0.17x | 2.99x | 26.08x | 30.69x | +4.78% | 101B | ||
12.79x | 4.211 | 2.61x | 2.48x | 7.36x | 8.51x | +3.70% | 87.89B | ||
30.36x | 5.995 | 2.56x | 9.14x | 19.25x | 20.62x | +1.29% | 78.63B | ||
45.35x | 5.816 | 5.56x | 4.94x | 28.4x | 37.1x | +1.18% | 69.4B | ||
24.93x | 2.116 | 0.63x | 3.81x | 15.09x | 16.94x | +1.63% | 47.44B | ||
58.15x | 0.9002 | -2.56x | 2.4x | 10.07x | 36.09x | +4.74% | 46.62B | ||
Average | 42.15x | 11.03 | 0.44x | 5.70x | 16.20x | 19.93x | +2.78% | 225.24B | |
Weighted average by Cap. | 40.42x | 19.52 | 0.44x | 8.84x | 21.69x | 24.32x | +2.35% |
- Stock Market
- Equities
- BAYN Stock
- Sector Bayer AG
- Sector valuations
MarketScreener is also available in this country: United States.
Switch edition